November 12, 2020
Medicare to cover monoclonal antibody COVID-19 treatments
Editor's Note
The Centers for Medicare and Medicaid Services (CMS) on November 10 announced that Medicare will cover out-of-pocket costs for monoclonal antibody drugs for COVID-19 during the public health emergency.
The agency’s coverage includes Eli Lilly’s bamlanivimab, which recently received an emergency use authorization from the Food and Drug Administration.
Medicare won’t pay for monoclonal antibody products that providers receive for free, but it will pay for the infusion.
Free Daily News
- Study: ERAS protocol reduces opioid use after cardiac surgery
- Study: Prehabilitation reduces surgical complications, speeds recovery
- Commentary: Studies show how surgeon decisions follow the money
- Proposed HIPAA updates would improve cybersecurity, increase costs for healthcare providers
- Study: EMR data can enhance hand hygiene compliance, infection prevention
- Study: Machine learning model improves perioperative pain assessment
- Call for improved suicide risk screening in ASCs aims to strengthen safety protocols
- Study: Perioperative pregabalin reduces risk of kidney decline compared to gabapentin
- Medical school diversity declines after Supreme Court ruling
- Surgeons risk losing ground as transcatheter tricuspid valve interventions rise
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement